Mirvie Receives FDA Breakthrough Device Designation for First Test Designed to Indicate Risk of Preeclampsia Months Before Symptoms Occur

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the company received U.S. Food and Drug Administration (FDA) Breakthrough Device designation for its test to indicate a woman’s individualized risk of developing preeclampsia before symptoms occur. The test is powered by the proprietary Mirvie RNA platform,...

Click to view original post